Applications

1584 – Radionuclide Imaging for for the diagnosis of transthyretin amyloid cardiomyopathy

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New MBS item.

Service or technology in this application

Radionuclide scintigraphy with 99mTc-labeled pyrophosphate (PYP), 99mTC-labeled oxidronate (HDP) or 99mTc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) is sensitive and specific for imaging cardiac ATTR amyloid and enables a diagnosis of ATTR-CM. A standard protocol includes whole-body scans after injection. Heart and whole-body retention and heart to whole-body retention ratio can be semi-quantitatively analysed from early whole-body counts.

Type: Therapeutic

Medical condition this application addresses

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease characterised by accumulation of amyloid fibrils composed of misfolded transthyretin protein in the heart. Misfolded monomers or oligomers of transthyretin are deposited in the myocardium, leading to cardiomyopathy and symptoms of heart failure.

ATTR-CM is a late-onset disease occurring predominately in male patients aged 60 years or older. ATTR-CM can be inherited as an autosomal dominant trait caused by pathogenic mutations in the transthyretin gene TTR (ATTRm) or by deposition of wild-type transthyretin protein (ATTRwt), previously called senile systemic amyloidosis.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 1 to 2 August 2019